Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” for the second consecutive year

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative biopharmaceutical company specialized in the development
of orphan oncology drugs, has been awarded for the second consecutive year the
“Silver Governance” in the small and midcap companies category at the Twelfth
Annual Corporate Governance Awards held by the French financial magazine AGEFI
on September 16, 2015.

The Corporate Governance Prizes reward listed companies with the best corporate
governance practices, in particular as regards the composition of the companies’
Board of Directors, the transparency of communication, the functioning of
corporate bodies, social responsibility, and risk management. The awards are
based on the results of a survey of finance industry professionals. The
methodology is validated by a steering committee which identifies the companies’
good practices based on data provided in the annual reports and reference
documents.

“We are very happy to, once again, be awarded with this prize which reflects the
excellence of our governance and our efforts to implement the best corporate
processes. These are key in strengthening our shareholders’ and the market’s
confidence in Onxeo. Therefore, we will continue to ensure that we are up to the
highest standards in these fields,” commented Patrick Langlois, Chairman of the
Board of Directors of Onxeo.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive
final results
Beleodaq® (belinostat): registered in the US in 2nd line treatment of peripheral
T-cell lymphoma

For more information, visit the website www.onxeo.com

To receive our press releases and newsletters, please register on:
http://www.onxeo.com/en/newsletter/

Follow us on twitter @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
Contacts
Onxeo S.A.
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie, +33 6 64 18 99 59 / +33 6 47 38 90 04
onxeo@alizerp.com